GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzychem Lifesciences Corp (XKRX:183490) » Definitions » Equity-to-Asset

Enzychem Lifesciences (XKRX:183490) Equity-to-Asset : 0.92 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enzychem Lifesciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Enzychem Lifesciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩192,447 Mil. Enzychem Lifesciences's Total Assets for the quarter that ended in Mar. 2024 was ₩208,400 Mil. Therefore, Enzychem Lifesciences's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.92.

The historical rank and industry rank for Enzychem Lifesciences's Equity-to-Asset or its related term are showing as below:

XKRX:183490' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.56   Med: 0.83   Max: 0.92
Current: 0.92

During the past 10 years, the highest Equity to Asset Ratio of Enzychem Lifesciences was 0.92. The lowest was 0.56. And the median was 0.83.

XKRX:183490's Equity-to-Asset is ranked better than
95.58% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs XKRX:183490: 0.92

Enzychem Lifesciences Equity-to-Asset Historical Data

The historical data trend for Enzychem Lifesciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzychem Lifesciences Equity-to-Asset Chart

Enzychem Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.59 0.56 0.82 0.92

Enzychem Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 0.92 0.90 0.92 0.92

Competitive Comparison of Enzychem Lifesciences's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Enzychem Lifesciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzychem Lifesciences's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzychem Lifesciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Enzychem Lifesciences's Equity-to-Asset falls into.



Enzychem Lifesciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Enzychem Lifesciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=193515.937/211545.507
=0.91

Enzychem Lifesciences's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=192446.79/208400.022
=0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzychem Lifesciences  (XKRX:183490) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Enzychem Lifesciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Enzychem Lifesciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzychem Lifesciences (XKRX:183490) Business Description

Traded in Other Exchanges
N/A
Address
27 Gangnamdae-ro Seocho-gu, 10th Floor, aT Center, Seoul, KOR, 135-280
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.

Enzychem Lifesciences (XKRX:183490) Headlines

No Headlines